Royal Bank of Canada Buys 21,039 Shares of Smith & Nephew SNATS, Inc. $SNN

Royal Bank of Canada raised its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 6.7% in the first quarter, according to its most recent filing with the SEC. The firm owned 337,118 shares of the medical equipment provider’s stock after purchasing an additional 21,039 shares during the quarter. Royal Bank of Canada’s holdings in Smith & Nephew SNATS were worth $10,713,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Equity Investment Corp increased its position in shares of Smith & Nephew SNATS by 3.9% during the fourth quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock worth $246,000 after buying an additional 285 shares during the period. Smartleaf Asset Management LLC raised its stake in Smith & Nephew SNATS by 13.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,820 shares of the medical equipment provider’s stock worth $93,000 after buying an additional 334 shares during the last quarter. Cary Street Partners Financial LLC lifted its holdings in Smith & Nephew SNATS by 1.8% in the fourth quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock valued at $665,000 after buying an additional 365 shares during the period. Parallel Advisors LLC lifted its holdings in Smith & Nephew SNATS by 20.0% in the first quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after buying an additional 387 shares during the period. Finally, Vise Technologies Inc. boosted its position in Smith & Nephew SNATS by 4.7% during the third quarter. Vise Technologies Inc. now owns 9,642 shares of the medical equipment provider’s stock valued at $350,000 after acquiring an additional 437 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on SNN shares. Sanford C. Bernstein set a $31.85 price target on Smith & Nephew SNATS in a report on Monday, May 11th. Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Barclays lowered Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday. Morgan Stanley reaffirmed an “overweight” rating on shares of Smith & Nephew SNATS in a research note on Wednesday. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday. Two research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Stock Performance

SNN stock opened at $30.10 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.25. The company’s 50-day moving average is $30.46 and its 200-day moving average is $32.12. Smith & Nephew SNATS, Inc. has a 1 year low of $28.56 and a 1 year high of $38.79.

Smith & Nephew SNATS Dividend Announcement

The company also recently declared a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be issued a $0.312 dividend. The ex-dividend date is Friday, October 2nd. This represents a yield of 205.0%.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.